Most-Favored-Nation Drug Deals Now Cover 89% of the Market. Your Plan's Invoice Won't Change.

On August 31, the White House announced most-favored-nation pricing agreements with nine more pharmaceutical manufacturers: Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB. That brings the total to 26 companies, which the administration says represent 89% of the branded drug market, alongside a pledge of $19.6 billion in U.S. manufacturing investment. Incyte separately agreed to align Jakafi's price with peer countries. If you run a self-funded plan, the question landing in your inbox this week is a simple one: if drug prices are coming down, why is our pharmacy renewal up eight percent? The honest answer is that these agreements price drugs for Medicaid, and a self-funded employer plan is not Medicaid. Understanding why requires knowing something most benefits leaders were never taught: the same tablet carries three different prices in this country, set by three different mechanisms, and the one your plan pays is the only one nobody at the podium was talking about.

The Misconception

The phrase "most-favored-nation pricing" sounds like a national price. It is not. It is a commitment by a manufacturer to give a specific purchaser a price no higher than the lowest price it charges in a basket of comparable countries. The purchaser in these agreements is the Medicaid program, delivered through the CMS Innovation Center's GENEROUS model, in which manufacturers pay a supplemental rebate large enough to bring the state's net price down to the international benchmark. The agreements also commit signatories to launch new medicines at prices aligned with peer countries, and, for cash-paying consumers, to list some products on TrumpRx.gov.

None of that touches a commercial pharmacy claim. Your plan buys drugs through a PBM at a price built from the wholesale acquisition cost (the manufacturer's published list price) minus a negotiated rebate. The manufacturer's Medicaid supplemental rebate is a separate check, written to a state, under a separate statute. The common assumption among plan sponsors is that a lower price "somewhere" must eventually pull commercial prices down. Under the current statutory design, the opposite pressure is at least as strong.

Three Prices for One Pill

It helps to see the three systems side by side, because the article you read in the trade press this week was describing only one of them.

Medicaid pays a statutory net price. Manufacturers owe a basic rebate of the greater of 23.1% of the average manufacturer price or the difference between AMP and "best price," the lowest price offered to essentially any commercial purchaser in the country. Add an inflation rebate if the list price has grown faster than CPI, add state supplemental rebates, and you arrive at a net price that, for many brands, was already 50% or more below list before any MFN deal existed. The Urban Institute analysis published in JAMA on July 17 estimated that applying MFN benchmarks to the 82 largest Medicaid brand drugs would save about $8.6 billion a year, roughly 35% of net Medicaid spending on those drugs, and that three states with aggressive existing supplemental rebates would save nothing at all. That last detail matters: Medicaid was already the cheapest buyer in the room, and MFN makes it cheaper.

Medicare Part D, for a small list of selected drugs, pays a negotiated maximum fair price. Beginning January 1, 2027, semaglutide products (Ozempic, Wegovy, Rybelsus) carry an MFP of $274 for a 30-day supply, about 71% below list. Novo Nordisk said plainly when the price was announced that it "applies only to Medicare beneficiaries and does not change prices for patients with commercial insurance, Medicaid, or those using the self-pay program."

Commercial plans pay list minus rebate, with the rebate negotiated by a PBM whose economics may or may not be aligned with yours, and with the net price invisible to you until a reconciliation arrives a quarter or two later. There is no statute, no benchmark, and no international reference. There is a contract.

The reason the three systems can diverge this far without collapsing into one is a single clause in the Medicaid rebate statute: prices and rebates paid to Medicaid are excluded from the calculation of best price. That exclusion is precisely what allows a manufacturer to give a state an MFN-level net price without triggering the same price for every commercial contract in the country. It is the load-bearing wall of the whole structure, and it is why the announcement can be true, significant for state budgets, and irrelevant to your renewal at the same time.

Why Employers Miss This

Three reasons, none of which reflect poorly on a benefits team.

First, the headline metric is real. Prescription drug prices as measured by the consumer price index fell 3.1% in the twelve months ending July, reported as the steepest annual decline in more than sixty years. That index captures list-price cuts on a handful of very large products (Novo's 2027 list prices for Wegovy and Ozempic will be $675, down 35% to 50%) and cash-pay channels. It does not capture net commercial cost after rebates, which is the number your plan actually pays and which can move in the opposite direction when a manufacturer lowers list and shrinks the rebate at the same time.

Second, the announcements are written for consumers and state budget directors. Coverage of "89% of the market" and "$600 billion in savings over the decade" (the Council of Economic Advisers' figure) is built on Medicaid and cash-pay channels. TrumpRx, the cash-pay storefront created alongside the first wave of deals, covered fewer than 12% of the roughly 800 brand-name drugs sold by the original seventeen signatories as of July, with inconsistent advantages over existing discount channels. The trade press has been skeptical for the same reason. STAT's September 2 analysis called the second round "headline-grabbing midterm messaging," and Harvard's Luca Maini told TIME that "the main benefit here is not to the patients using the drugs, but to the fiscal health of the program."

Third, the incentive to sign was never about the commercial market. Section 232 tariffs of up to 100% on patented pharmaceutical imports took effect July 31 for most manufacturers, with seventeen large companies deferred to September 29. A signed MFN agreement paired with an approved onshoring plan reduces that tariff to zero through January 2029. Truist's note to investors after the August 31 announcement described MFN as having "migrated from existential threat" to a manageable cost, with "business as usual" expected. A company that gives Medicaid a lower net price in exchange for avoiding a 100% tariff on its imported product has made a rational trade. The commercial market's role in that trade is to absorb whatever margin the manufacturer needs to recover.

Five Checkpoints Before You Accept the "Prices Are Falling" Narrative

1. Separate list-price movement from net-price movement in your own data. Pull the top twenty brands by spend and compare WAC per unit and net cost per unit (after all rebates, including manufacturer administrative fees) for the last eight quarters. If WAC fell and net cost did not, the rebate absorbed the cut. If neither moved, the announcements did not reach you, which is the expected result.

2. Ask what happens to your rebate guarantee when list prices reset. A guarantee expressed in dollars per brand script, or as a percentage discount off average wholesale price, was underwritten against the old list price. Semaglutide's 2027 list price cut is the live test: a plan with a $520-per-brand-script minimum rebate guarantee may find the PBM invoking a "market event" clause to reprice it, and a plan whose discount guarantee is measured off AWP will see "performance" deteriorate on a product whose net cost improved. Ask for the clause by name before January 1.

3. Read the new-launch commitment carefully. The agreements commit signatories to launch new medicines at prices "aligned" with peer countries. There are two ways to align: lower the U.S. price to Europe's, or raise Europe's toward the U.S. Manufacturers have said publicly for a year that they intend to negotiate harder abroad. For your plan, a new specialty launch at an "MFN-aligned" price may still be a $40,000-a-month drug, because the alignment is relative, not absolute. Rasonque, approved August 26 for metastatic pancreatic cancer, launched at $39,800 for a thirty-day supply, in the same window as these deals.

4. Check whether your PBM is contracting for MFN-adjacent products differently. Manufacturers with narrow margins on Medicaid and Medicare may seek to preserve commercial economics through larger rebates tied to exclusive formulary position, which raises the list price your members' coinsurance is calculated on. Your contract's formulary-rational disclosure right under CAA 2026 is the tool for this question; ask for net-cost rationale by class, not a summary.

5. Model tariff pass-through on your top imported brands. Generics and biosimilars are exempt from the Section 232 tariffs, but patented products from non-signatory manufacturers, and from signatories whose onshoring plans are not yet approved, are not. Manufacturers do not publish which products are imported, but your PBM's formulary team and your consultant can identify the largest at-risk brands. There is no evidence yet that tariffs have moved WAC; the September 29 deadline is when that evidence begins to accumulate.

An Illustrative Example

Assume a 3,000-employee self-funded plan spending $9.8 million a year on prescriptions, with $6.2 million of that on brands, and assume the plan's brand net cost averages 38% below list after rebates. Suppose that, across the plan's top twenty brands, manufacturers respond to MFN and MFP pressure by cutting list prices an average of 20% while reducing rebates from 38% to 22% of the new list. On a $100 unit, the old net was $62. The new net is $80 times 0.78, or $62.40. The plan's reported "discount" fell from 38% to 22%, its rebate check shrank by roughly $900,000, its per-script guarantee is now underwater, and its actual net cost is unchanged to the dollar. Every headline about falling drug prices was true. The plan is in a worse negotiating position than it was a year ago, and its trend report shows nothing because nothing happened. These figures are illustrative, not sourced to a specific contract.

The analogy worth keeping is airline pricing. A carrier can announce that it has cut fares for a government travel contract, for a corporate account, and for a promotional web sale, and every announcement can be accurate, while the price on the itinerary in front of you is set by an entirely different rule. The announcement is not false. It is simply not about your ticket.

What to Watch Next

September 29 is the date the deferred tariffs take effect for the seventeen manufacturers that have not yet secured onshoring approval; watch fourth-quarter WAC files for the first signs of pass-through. January 1, 2027 is when Medicare's negotiated semaglutide price and Novo's new list prices take effect at the same moment, which will make the "list down, net flat" pattern visible in commercial claims for the largest brand category most plans have. And watch for the operative text of the MFN agreements themselves, which the administration has not released and which Senator Warren has demanded; the launch-price and Medicaid-access provisions will be judged on their definitions, which is a lesson plan sponsors already know from their own contracts.

Bottom Line

The agreements are meaningful public policy for Medicaid, for state budgets, and for the manufacturers who avoided a 100% tariff. They do not set, cap, or reference the price a self-funded plan pays, because the Medicaid rebate statute was written to keep those prices separate. The plans best positioned for 2027 are the ones that can already tell the difference between their list price and their net price on every brand they buy, and that have read the reset clauses in their contracts before January makes them relevant.